699P - Metformin use is associated with improved survival in diabetic pancreatic cancer patients

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Cancer in Special Situations
Pancreatic Cancer
Presenter Se Hyun Kim
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors S.H. Kim1, M.H. Kim2, B. Kang3, J.B. Ahn4, H.J. Choi3
  • 1Internal Medicine, Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 2Department Of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul/KR
  • 3Internal Medicine, Yonsei Univ. Severance hospital, 120-752 - Seoul/KR
  • 4Department Of Medical Oncology, Yonsei University College of MedicineDepartment of Internal Medicine, KR-120-752 - Seoul/KR



Accumulating evidence suggests that metformin use is associated with better survival in cancer patients with diabetes mellitus. The aim of this study was to determine the effect of metformin exposure on survival in patients with pancreatic cancer.


We conducted a retrospective cohort study of patients with diabetes and pancreatic cancer treated at Yonsei Cancer Center (Seoul, Korea) from 2005 to 2010. Clinical data on diabetes and pancreatic cancer were obtained from electronic medical record database and survival data were retrieved from the tumor registry at Yonsei Cancer Center. Survival analysis was carried out using a Kaplan-Meier plot, log-rank test, and Cox proportional hazards regression models were used.


The study included 428 patients with type 2 diabetes mellitus and pancreatic cancer. The median overall survival (OS) in metformin group (n = 111) was 12.6 months and 7.6 months in non-metformin group (n = 317; P = 0.001, log-rank test). Among metastatic patients (n = 220), median OS was greater in metformin group (6.7 months) than non-metformin group (5.4 months), but it was not statistically significant (P = 0.057, log-rank test). In multivariate model, adjusting for ECOG performance status, CA 19-9, stage (resectable/unresectable/metastatic), body mass index (BMI) and number of organ involvement, metformin use was independently associated with improved OS in all patients (HR = 0.78; 95% CI, 0.62-0.98; P = 0.032).


Our finding suggests that metformin use might be associated with improved survival in pancreatic cancer patients with type 2 diabetes.


All authors have declared no conflicts of interest.